These spatial findings suggest that Treg‐mediated immunosuppression, potentially driving an M2 macrophage phenotype, contributes to ICI resistance, whereas macrophage proximity to tumour cells and effector CD4+ T cell enrichment in mixed tumour neighbourhoods correlate with response, offering insights into overcoming resistance to cancer therapy. This evidence concerns the gene CD4 and neoplasm.